Related Experiment Video
Updated: Jun 9, 2026

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein
Published on: October 12, 2017
High-density lipoprotein antioxidant function is associated with lipid profiles and lipid-lowering therapy
Hong-Yu Cao1,2, Zhi-Wei Mo1,2, Zhen-Sheng Ma1,2
1Division of Cardiac Surgery, Cardiovascular Diseases Institute, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, 510080, China.
Insights
High-density lipoprotein (HDL) antioxidant function is linked to lipid profiles in coronary artery disease (CAD) patients. Lipid-lowering therapy enhances HDL antioxidant function, suggesting its potential as a treatment efficacy indicator.
Area of Science:
- Cardiovascular Medicine
- Biochemistry
- Clinical Chemistry
Background:
- Dyslipidemia is a key risk factor for coronary artery disease (CAD).
- The role of high-density lipoprotein (HDL) antioxidant function in CAD and its interaction with lipid-lowering therapy requires further investigation.
- Understanding HDL's antioxidant capacity is crucial for managing CAD patients.
Purpose of the Study:
- To analyze the association between HDL antioxidant function, lipid profiles, and lipid-lowering therapy in CAD patients.
- To evaluate HDL antioxidant function as a predictor of CAD.
- To explore the impact of lipid-lowering therapy on HDL antioxidant function.
Main Methods:
- Recruited 1,000 CAD patients and 200 healthy controls.
- Measured HDL lipid peroxide content, normalized by HDL cholesterol (HDL-C) to define HDL antioxidant function (nHDLox).
- Analyzed associations between nHDLox, lipid profiles, CAD severity, lipid-lowering therapy, fasting blood glucose, and inflammatory markers.
Main Results:
- nHDLox levels were elevated in CAD patients and correlated with CAD severity.
- nHDLox demonstrated superior predictive value for CAD compared to triglyceride-glucose index and HDL-C.
- nHDLox positively correlated with total cholesterol, LDL-C, triglycerides, fasting blood glucose, and inflammatory markers.
- Lipid-lowering therapy was associated with improved HDL antioxidant function in CAD patients with controlled LDL-C.
Conclusions:
- HDL antioxidant function is significantly associated with lipid profiles and inflammatory markers in CAD.
- nHDLox can serve as a potential biomarker for CAD prediction and monitoring treatment efficacy.
- Lipid-lowering therapy appears to enhance HDL antioxidant function in CAD patients.
Abstract:
Dyslipidemia is an important risk factor for coronary artery disease (CAD). However, the relationship between high-density lipoprotein (HDL) antioxidant function and plasma lipid profile has not been fully investigated. Lipid-lowering therapy is recommended in patients with CAD. The relationship between HDL antioxidant function and lipid-lowering therapy remains unclear. This study aimed to analyze the association between HDL antioxidant function, lipid profiles, and lipid-lowering therapy in patients with CAD. To investigate this, we recruited 1,000 patients with CAD and 200 healthy subjects. HDL lipid peroxide content was measured and normalized by HDL cholesterol (HDL-C) levels to represent HDL antioxidant function (nHDLox). nHDLox levels were compared across different CAD severities. The association between nHDLox and lipid profiles was also analyzed. The difference in nHDLox between patients who received lipid-lowering therapy and those who did not was analyzed. A correlation analysis was performed to investigate the association between nHDLox and fasting blood glucose and inflammatory markers. Results demonstrated that nHDLox levels were elevated in patients with CAD compared to healthy subjects, and were also higher in patients with acute coronary syndrome and CAD combined with three-vessel disease. Receiver operating characteristic curve analysis showed that nHDLox was better than triglyceride-glucose index and HDL-C levels in predicting CAD. nHDLox positively correlated with total cholesterol, low-density lipoprotein cholesterol (LDL-C), and triglyceride levels. Further analysis showed an approximately "L"-shaped relationship between nHDLox and HDL-C levels. Moreover, among CAD patients with LDL-C < 3.0 mmol/L, nHDLox was significantly reduced in the lipid-lowering therapy group compared to that in the group without lipid-lowering therapy. Furthermore, nHDLox positively correlated with fasting blood glucose levels and inflammatory markers. In conclusion, HDL antioxidant function is associated with lipid profiles. Lipid-lowering therapy improves HDL antioxidant function in patients with CAD, and nHDLox may serve as an indicator for the efficacy of such treatment.
Related Concept Videos
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Atherosclerosis III: Management
Cholesterol: Significance and Regulation
Considering cholesterol and...
Blood Studies for Cardiovascular System III: Serum Lipid Profile
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...
Lipid-derived Compounds in the Human Body
Fat-soluble Vitamins
Fat-soluble vitamins, including vitamins A, D, E, and K, are required in minimal quantities, but their deficiencies can lead to severely abnormal physiological conditions. For example, vitamin A deficiency can cause night blindness, dry skin, delayed...
Lipids: Dietary Sources and Requirements
